海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02637 海西新药

未开盘 07-23 16:08:04

180.900

+1.200

+0.67%

最高183.900	最低174.000	成交量11.27万
今开179.000	昨收179.700	日振幅5.51%
总市值142.38亿	流通市值142.38亿	总股本7,871万
成交额2,006万	换手率0.14%	流通股本7,871万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02637","market":"HK","secType":"STK","nameCN":"海西新药","latestPrice":180.9,"timestamp":1784794084417,"preClose":179.7,"halted":0,"volume":112698,"delay":0,"changeRate":0.006677796327212116,"floatShares":78707270,"shares":78707270,"eps":2.94980711328566,"marketStatus":"未开盘","change":1.2,"latestTime":"07-23 16:08:04","open":179,"high":183.9,"low":174,"amount":20063680,"amplitude":0.055092,"askPrice":180.9,"askSize":150,"bidPrice":177.1,"bidSize":150,"shortable":3,"etf":0,"ttmEps":2.8803998870907037,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":0,"adr":0,"listingDate":1760889600000,"exchange":"SEHK","adjPreClose":179.7,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.7205754474781872,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02637/tweets","defaultTab":"tweets","newsList":[{"id":"2653223443","title":"港股午评|恒生指数午盘涨0.03%    芯片股全线走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2653223443","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653223443?lang=zh_cn&edition=full","pubTime":"2026-07-21 12:00","pubTimestamp":1784606453,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.03%，涨7点，报25150点；恒生科技指数涨1.83%。港股午盘成交1576亿港元。消息称智谱建成大型AI数据中心，全部采用国产芯片，半导体全线大涨。智谱涨超25%，落地1GW级国产AI算力数据中心建设，完成对中科加禾收购；MiniMax涨超11%。先导智能涨超7%，拟2亿港元至4亿港元回购H股股份。中国龙工涨超8%，产销规模稳步增长， 上半年纯利最高同比预增27%。恒生创新药指数调整，海西新药跌超6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1163","300450","603986","LU0359202008.SGD","LU0359201885.HKD","BK1179","BK1589","WOOD","03423","09088","BK1223","03986","03037","02637","03417","83115","LU1282649141.HKD","02837","01347","NDGPY","03339","LU0488056044.USD","LU1211504680.USD","IE0034224299.USD","LU2929501877.USD","03419","BK1614","LU0593848301.USD","LU0384037296.USD","LU2187417386.USD","SG9999004220.SGD","03088","09067","03115","TCHI","02833","02689","LU1282649810.SGD","BK1514","HK0000252160.HKD","KBDCY","MCHS","LU1813983027.USD","FPA","07200","BK1170","09115","LU0052750758.USD","688981","MCHmain","01888","LU2351347302.SGD","BK1181","07300","SG9999001093.SGD","LU0320764599.SGD","BK1505","HHImain","SG9999006597.SGD","00100","03032","SG9999014674.SGD","HSI","LU1808992512.USD","LU0708995583.HKD","LU2039709279.SGD","513600","HK0000500386.USD","02513","688347","02800","LU1282649067.USD","HK0000252152.HKD","BK1171","00981","03067","07226","BK1607","82800","BK1190","BK1551","00148","SG9999002950.SGD","03277","BK1526","BK1610","LU1023057109.AUD","LU0648948544.HKD","03033","06880","BK1506","LU0359201612.USD","03858","LU0314109678.HKD","00470","07552","HSTECH","BK1117","BK1548","07500","BK1183","BK1191","LU1328277881.USD","LKHLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100798304","title":"福建海西新药创制股份有限公司（02637）将于8月4日召开2026年第一次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=1100798304","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100798304?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:50","pubTimestamp":1784112633,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司7月15日公告，公司已发出召开2026年第一次临时股东会的通告，会议定于2026年8月4日（星期二）上午十时在中国福建省福州市仓山区建新镇金达路177号B座一楼会议室举行。\\n\\n根据公告，2026年第一次临时股东会的所有决议案将按香港联合交易所有限公司证券上市规则以投票方式表决。记录日期为2026年8月4日；H股股东如欲出席并投票，须在2026年7月29日16时30分前完成股份过户登记。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134835610","title":"海西新药（02637.HK）董事会换血：王忻琨辞任非执董，提名陈廷泽出任执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=1134835610","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134835610?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:41","pubTimestamp":1784112075,"startTime":"0","endTime":"0","summary":"福建海西新药创制股份有限公司7月15日公告称，公司非执行董事王忻琨因工作调动辞任，其离任自公司股东会选举新董事之日起生效。董事会已接受其辞任，并对其任内贡献表示感谢。与此同时，公司董事会提名陈廷泽为执行董事候选人，并已于2026年7月9日召开的提名委员会会议及7月15日的董事会会议审议通过。若获股东会批准，陈廷泽的任期将自股东会选举通过之日起，至第二届董事会任期届满之日止。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452821","title":"海西新药(02637.HK)：陈廷泽获提名为执行董事候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452821?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:37","pubTimestamp":1784111829,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651452884","title":"海西新药(02637.HK)建议委任容诚为核数师","url":"https://stock-news.laohu8.com/highlight/detail?id=2651452884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651452884?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:36","pubTimestamp":1784111760,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150967054","title":"海西新药拟改用中国企会准则并更换核数师　审计费用拟降逾五成","url":"https://stock-news.laohu8.com/highlight/detail?id=1150967054","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150967054?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:35","pubTimestamp":1784111735,"startTime":"0","endTime":"0","summary":"海西新药7月15日公告，公司董事会已通过决议，自2026年6月30日止半年度财务报告起，统一采用中国企业会计准则编制财务报表，并拟在临时股东大会上提请股东批准更换外聘核数师。董事会表示，统一会计准则有助于提升信息披露效率并降低编制成本。董事会已向股东承诺，将适时向股东寄发载有更换核数师详情的通函，并召开临时股东大会审议相关议案。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651336594","title":"港股异动 | 海西新药(02637.HK)涨超4% HXP089用于治疗GBM的新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2651336594","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651336594?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:04","pubTimestamp":1784081068,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137318446","title":"海西新药HXP089治疗胶质母细胞瘤IND获批 迈入临床阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1137318446","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137318446?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:11","pubTimestamp":1784020270,"startTime":"0","endTime":"0","summary":"2026年7月14日，福建海西新药创制股份有限公司发布自愿公告称，公司自主研发的HXP089项目用于治疗胶质母细胞瘤的新药临床试验申请已获国家药品监督管理局药品审评中心批准，获准开展相关临床研究。HXP089是基于公司自主创新小分子药物研发平台MultiSel-Opt开发的新一代化学小分子选择性多靶点创新药，具备通过血脑屏障的能力，拟用于解决胶质母细胞瘤复发后缺乏有效标准治疗药物的临床需求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651176160","title":"海西新药(02637)：HXP089 项目用于治疗胶质母细胞瘤的新药临床试验申请(IND)获得国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651176160","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651176160?lang=zh_cn&edition=full","pubTime":"2026-07-14 17:10","pubTimestamp":1784020215,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，本公司自主研发的HXP089项目用于治疗胶质母细胞瘤的新药临床试验申请，已获国家药品监督管理局药品审评中心批准，同意开展相关临床研究。HXP089的研发，有望解决上述治疗空缺，满足全球患者的临床急需。本次获批将支持开展相关临床研究，以评估HXP089在目标患者中的安全性、耐受性及初步有效性特征。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467213.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02637","BK1191","BMED","IND","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650867903","title":"海西新药(02637.HK)存仓市值总计20.13亿港元 公司股东将987.33万股股票存入招银国际证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2650867903","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650867903?lang=zh_cn&edition=full","pubTime":"2026-07-10 08:25","pubTimestamp":1783643112,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145733208","title":"海西新药（02637）自主研发C019199片启动骨肉瘤III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1145733208","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145733208?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:42","pubTimestamp":1783586546,"startTime":"0","endTime":"0","summary":"2026年7月9日，福建海西新药创制股份有限公司在港交所发布自愿公告称，其自主研发的C019199片已正式启动针对既往至少二线治疗失败骨肉瘤患者的III期临床试验。该III期研究为随机、对照、开放、多中心试验，方案编号为HXP019-CTPIII-02，计划在全国多家研究中心招募约120名受试者，比较C019199片与吉西他滨联合多西他赛的有效性与安全性。本次III期临床试验的启动，标志着公司在晚期骨肉瘤治疗领域的创新管线进入关键阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110718545","title":"海西药业启动C019199片治疗骨肉瘤三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1110718545","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110718545?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:42","pubTimestamp":1783586524,"startTime":"0","endTime":"0","summary":"海西药业股份有限公司宣布，已正式启动其新药C019199片用于治疗骨肉瘤的三期临床试验。C019199片作为海西药业自主研发的创新药物，其前期研究结果已显示出潜在的治疗前景。该阶段旨在进一步评估C019199片在更大患者群体中的疗效与安全性，为最终向监管机构提交新药上市申请提供关键数据支持。市场密切关注海西药业此次临床试验的进展。成功与否，将直接影响C019199片未来的商业化前景，并对公司的长期价值产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650947562","title":"海西新药(02637)：C019199片启动骨肉瘤III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650947562","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650947562?lang=zh_cn&edition=full","pubTime":"2026-07-09 16:39","pubTimestamp":1783586357,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海西新药 发布公告，公司自主研发的C019199片正式启动针对既往至少二线治疗失败的骨肉瘤的III期临床试验，相关信息已获中国国家药品监督管理局药品审评中心药物临床试验登记与资讯公示平台公示。C019199片是海西新药基于自主构建的MultiSel-Opt小分子创新药物研发平台开发的全球首创多靶点肿瘤免疫调节剂。C019199片的III期临床启动，标志着集团在晚期骨肉瘤治疗领域的创新管线迈出了关键一步，有望为患者提供全新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4134","02637","IBBQ","BMED","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173359281","title":"海西新药6月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1173359281","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173359281?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:52","pubTimestamp":1783327945,"startTime":"0","endTime":"0","summary":"海西新药于2026年7月6日发布的月度股份变动报告显示，截至2026年6月30日，公司注册股本维持78,707,270股，面值每股人民币1元，注册股本总额为人民币78,707,270元，较上个月无任何增减变化。根据报告披露，6月份公司已发行普通股数量为78,707,270股，并无库藏股，亦无新增发行或回购注销活动。公司在当月未发生任何股份期权、权证及可换股票据的授出、行使或失效事宜，整体股本结构稳定。本次月报由联席公司秘书张俊环签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111402711","title":"港股创新药概念股集体上扬，海西新药涨超10%，诺诚健华涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111402711","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111402711?lang=zh_cn&edition=full","pubTime":"2026-07-06 09:42","pubTimestamp":1783302132,"startTime":"0","endTime":"0","summary":"7月6日，港股创新药概念股集体上扬，$海西新药(02637)$涨超10%，$诺诚健华(09969)$涨超8%，$荣昌生物(09995)$、$乐普生物(02157)$、$康诺亚-B(02162)$涨超5%，$三生制药(01530)$、$信达生物(01801)$、$先声药业(02096)$涨超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK1191","VXUS","159992","BK1574","IBBQ","BK1161","06978","02637","MEDX","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648865543","title":"【券商聚焦】国泰海通证券维持海西新药(02637)“增持”评级 指HXP056具出海潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2648865543","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648865543?lang=zh_cn&edition=full","pubTime":"2026-07-03 14:00","pubTimestamp":1783058441,"startTime":"0","endTime":"0","summary":"该行认为，公司的核心创新药资产HXP056有望解决现有注射剂产品的核心痛点，具有极好的商业化开发与出海潜力。研报强调，临床前药代动力学数据显示HXP056具有极好的眼部富集能力，同时能在外周系统被快速代谢。风险提示包括HXP056疗效不及预期、系统安全性风险及临床与海外推进不及预期等。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985091","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","02637","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328277881.USD","LU1226288253.USD","02637","LU0880133367.SGD","LU1993786604.SGD","LU2476274308.USD","IE00BZ08YR35.GBP","LU0417516902.SGD","LU1226287529.USD","IE00BZ08YS42.EUR","09995","09926","IE00B543WZ88.USD","BK1583","LU0326950275.SGD","LU0417516571.SGD","01530","06855","01093","02157","BK1574","LU0348783233.USD","BK1141","LU0067412154.USD","LU1969619763.USD","LU0140636845.USD","LU0634319403.HKD","06978","IE00B5MMRT66.SGD","02162","LU0348784397.USD","HK0000165453.HKD","LU0315179316.USD","LU0348767384.USD","LU1008478684.HKD","LU1960683339.HKD","159992","LU1226287792.SGD","LU0540923850.HKD","LU0348825331.USD","LU0348735423.USD","LU0348827113.USD","LU1961090484.USD","LU0348766576.USD","LU0072913022.USD","09969","LU1720050803.USD","LU1951186391.HKD","LU2476274720.SGD","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645201476","title":"海西新药(02637)存仓市值总计17.01亿港元 公司股东将988.26万股股票存入招银国际证券","url":"https://stock-news.laohu8.com/highlight/detail?id=2645201476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645201476?lang=zh_cn&edition=full","pubTime":"2026-06-22 08:32","pubTimestamp":1782088358,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月18日，海西新药(02637)出现仓位异动，存仓市值总计17.01亿港元，占比12.60%。该公司股东将988.26万股股票存入招银国际证券，持股比例增加12.56%。此前海西新药公布2025年业绩，收益为约5.82亿元，同比增长24.79%;净利约1.77亿元，同比增长30.09%;每股盈利为2.55元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02637","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643571732","title":"【券商聚焦】中信建投证券首予海西新药“买入”评级 指其创新管线进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2643571732","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643571732?lang=zh_cn&edition=full","pubTime":"2026-06-16 15:47","pubTimestamp":1781596045,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，海西新药 2025年业绩符合预期，营收达5.82亿元，同比增长24.8%，收入增长主因药品市场份额持续提升。净利润1.77亿元，同比增长30.1%。中信建投证券首次覆盖给予“买入”评级，预计公司2026至2028年收入分别为7.10亿元、8.53亿元、10.15亿元。风险包括新药研发不确定性及仿制药降价超预期带来的商业化压力。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NGI5ZWE4NDg5Y2ExYTk3MGU2NzMxODA4MzkxNTM=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983895","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643221793","title":"海西新药(02637.HK)首次覆盖：眼底病赛道大年 HXP056有望改写治疗范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2643221793","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643221793?lang=zh_cn&edition=full","pubTime":"2026-06-14 01:17","pubTimestamp":1781371022,"startTime":"0","endTime":"0","summary":"　　公司首创口服眼底病重磅药物：HXP056。2020-2024年全球品牌抗VEGF药物的总销售额呈现逐年递增趋势，2024年全球销售额近150亿美金，2025年因阿柏西普仿制药竞争整体市场首次出现下滑。HXP056利用MultiSel-Opt平台实现血视网膜屏障高穿透、系统暴露快速清除，临床前研究显示HXP056在小鼠和大鼠中，能够穿透BRB，眼球分布高，眼球中半衰期长，只在局部发挥疗效。　　HXP056临床进展顺利，I/II期数据积极。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260614/32279024.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hxpharma.com","stockEarnings":[{"period":"1week","weight":-0.0617},{"period":"1month","weight":0.1306},{"period":"3month","weight":-0.2386},{"period":"6month","weight":0.2442},{"period":"1year","weight":1.0938},{"period":"ytd","weight":0.3301}],"compareEarnings":[{"period":"1week","weight":0.0081},{"period":"1month","weight":0.0803},{"period":"3month","weight":-0.0295},{"period":"6month","weight":-0.0575},{"period":"1year","weight":-0.0128},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"福建海西新药创制股份有限公司成立于2012年3月27日。公司是一家处于商业化阶段的制药公司,集研发、生产及销售能力于一体,具备在研创新药的管线。公司在中国最大、增长最快的治疗领域拥有多元化的产品组合及管线。截至最后实际可行日期,公司已商业化的产品组合主要包括用于消化系统疾病、心血管系统疾病、内分泌系统疾病、神经系统疾病及炎症疾病的仿制药。根据灼识咨询的资料,该等治疗领域占2023年中国医药销售总额的25%以上。公司的创新药管线专注于具有各种适应症的在研药物,包括一款潜在属同类首款的在研肿瘤药物、一款潜在用于治疗湿性年龄相关性黄斑变性(wAMD)╱糖尿病性黄斑水肿(DME)╱视网膜静脉阻塞(RVO)的首款口服药物及另外两款处于临床前阶段,用于治疗肿瘤及呼吸系统疾病的创新在研药物。公司所有在研创新药均由内部以专有方式开发及发展。","exchange":"SEHK","name":"海西新药","nameEN":"HAIXI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海西新药,02637,海西新药股票,海西新药股票老虎,海西新药股票老虎国际,海西新药行情,海西新药股票行情,海西新药股价,海西新药股市,海西新药股票价格,海西新药股票交易,海西新药股票购买,海西新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海西新药(02637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海西新药(02637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}